VisiGen Targets Megabase-Per-Second Sequencer | GenomeWeb

VisiGen Biotechnologies has great ambitions: The company is not only targeting the $1,000 genome, but the $1,000 genome in less than a day.

The Houston-based company, which received an undisclosed equity investment from Applied Biosystems in late 2005, was founded in 2000 to develop a real-time single-molecule sequencing-by-synthesis technology that will eventually read 1 million bases of DNA per second. It hopes to offer a sequencing service based on its technology by the end of 2009, followed by an instrument release about two years after that.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: variation patterns in wheat lines, regulatory variation in Capsella grandiflora, and more.

A Rockefeller University researcher is using edited ants to explore complex biological systems, the New York Times writes.

There's a heritable aspect to how much time people spend online, the Los Angeles Times reports.

Stat News reports that Joseph Gulfo is another contender for FDA commissioner.